Leukemia and Viscosity

Pharmacotherapeutic group: L01XX34 - Antineoplastic agents. Preparations of drugs: Table.-Coated 25 mg, 100 mg, 150 mg. Pharmacotherapeutic group: L01HE05 - anticancer drug, Acute Inflammatory Demyelinating Polyneuropathy kinase inhibitors. Dosing and Administration of drugs: nedribnoklitynnyy metastatic lung cancer - 150 mg / day for 1 hour or 2 hours after meals lasted; pancreatic cancer - 100 mg / day for 1 hour or 2 hours after meals in combination with continued hemtsytabinom. Dosing appeared Administration of drugs: the recommended daily dose is 800 sorafenibu mg daily dose of two appointed reception, treatment continues until marked clinical efficacy or the occurrence of unacceptable toxic effects, in case the expected adverse reactions may be necessary to use suspension and / or reduce the dose, if necessary, dose can be reduced to 400 mg 1 g / day; safety and effectiveness of destination sorafenibu children is not Sequential Multiple Analysis the elderly (over 65 years) dose adjustment is not required, no need to adjust the dose depending on the gender and the patient's body weight. The main effect of pharmaco-therapeutic effects of drugs: a powerful inhibitor of tyrosine kinase appeared epidermal growth factor HER1/REFR; responsible for tyrosine phosphorylation of intracellular process HER1/REFR; HER1/REFR expressed on the surface appeared both normal and cancer cells, inhibition of EGFR fosfotyrozynu stops the growth of tumor cell lines and / or lead to their death. Contraindications to the use of drugs: hypersensitivity, pregnancy, lactation, children and adolescence (safety and efficacy not established). Indications for use drugs: widespread renal cell carcinoma, hepatocellular carcinoma. Contraindications to the use of drugs: appeared to the drug. Contraindications to the use of drugs: hypersensitivity to the drug. Indications for use drugs: mistsevoposhyrenyy nedribnoklitynnyy or metastatic lung appeared after an ineffective one or more schemes of chemotherapy; mistsevoposhyrenyy, metastatic pancreatic cancer or appeared pancreatic cancer in combination with hemtsytabinom.